Skip to main content
Top
Published in: Osteoporosis International 1/2019

01-01-2019 | Review Article

Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis: a systematic review and meta-analysis of randomized controlled trials

Authors: S. Lou, H. Lv, P. Yin, Z. Li, P. Tang, Y. Wang

Published in: Osteoporosis International | Issue 1/2019

Login to get access

Abstract

Combination therapy with parathyroid hormone (PTH) analogs and antiresorptive agents may be more effective than monotherapy for the treatment of osteoporosis. This study aimed to estimate the effectiveness and safety of this combination therapy for osteoporosis. MEDLINE, EMBASE, and Cochrane Library were searched from inception to May 1, 2018, including randomized controlled trials (RCTs) with a duration of at least 6 months on adults with osteoporosis treated with combination therapy versus monotherapy. Outcomes included fractures, bone mineral density (BMD) changes, and adverse events. A meta-analysis was performed using a random-effect model, to estimate risk ratios (RRs) for fractures, and mean differences (MDs) for BMD changes. A total of 19 RCTs and 2177 patients were included. Compared with monotherapy, combination therapy had an advantage of 36% (RR, 0.64; 95% confidence interval (CI), 0.42–0.98) regarding fracture risk reduction. It also appears to improve lumbar spine BMD by 4.06% (95%CI = 2.60–5.53) and total hip BMD by 1.89% (95%CI = 1.25–2.53). No RCT reported an increased risk of serious adverse events. Among patients with osteoporosis, combination therapy was superior to monotherapy regarding improvement of the lumbar spine and total hip BMD, without risk of serious adverse events. Combination therapy also had an advantage over monotherapy on fracture risk reduction. However, owing to the limited sample size, additional larger studies are required to confirm this benefit.
Appendix
Available only for authorised users
Literature
1.
go back to reference Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17(12):1726–1733PubMedCrossRef Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17(12):1726–1733PubMedCrossRef
2.
go back to reference Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359(9319):1761–1767PubMedCrossRef Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359(9319):1761–1767PubMedCrossRef
3.
go back to reference Budhia S, Mikyas Y, Tang M, Badamgarav E (2012) Osteoporotic fractures: a systematic review of U.S. healthcare costs and resource utilization. PharmacoEconomics 30(2):147–170PubMedCrossRef Budhia S, Mikyas Y, Tang M, Badamgarav E (2012) Osteoporotic fractures: a systematic review of U.S. healthcare costs and resource utilization. PharmacoEconomics 30(2):147–170PubMedCrossRef
4.
go back to reference Sattui SE, Saag KG (2014) Fracture mortality: associations with epidemiology and osteoporosis treatment. Nat Rev Endocrinol 10(10):592–602PubMedCrossRef Sattui SE, Saag KG (2014) Fracture mortality: associations with epidemiology and osteoporosis treatment. Nat Rev Endocrinol 10(10):592–602PubMedCrossRef
5.
go back to reference Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22(3):465–475PubMedCrossRef Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22(3):465–475PubMedCrossRef
6.
go back to reference Delmas PD (2008) Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases. J Clin Densitom 11(2):325–338PubMedCrossRef Delmas PD (2008) Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases. J Clin Densitom 11(2):325–338PubMedCrossRef
7.
go back to reference Reszka AA, Rodan GA (2003) Mechanism of action of bisphosphonates. Curr Osteoporos Rep. 1(2):45–52PubMedCrossRef Reszka AA, Rodan GA (2003) Mechanism of action of bisphosphonates. Curr Osteoporos Rep. 1(2):45–52PubMedCrossRef
8.
go back to reference Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, Jasqui S, Donley DW, Dalsky GP, Martin JS, Eriksen EF (2005) Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 20(7):1244–1253PubMedCrossRef Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, Jasqui S, Donley DW, Dalsky GP, Martin JS, Eriksen EF (2005) Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 20(7):1244–1253PubMedCrossRef
9.
go back to reference McClung MR, San MJ, Miller PD, Civitelli R, Bandeira F, Omizo M et al (2005) Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165(15):1762–1768PubMedCrossRef McClung MR, San MJ, Miller PD, Civitelli R, Bandeira F, Omizo M et al (2005) Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165(15):1762–1768PubMedCrossRef
10.
12.
go back to reference Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, Burnett-Bowie SAM, Neer RM, Leder BZ (2013) Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 382:50–56PubMedPubMedCentralCrossRef Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, Burnett-Bowie SAM, Neer RM, Leder BZ (2013) Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 382:50–56PubMedPubMedCentralCrossRef
13.
go back to reference Bilezikian JP (2008) Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr Osteoporos Rep 6:24–30PubMedCrossRef Bilezikian JP (2008) Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr Osteoporos Rep 6:24–30PubMedCrossRef
14.
go back to reference Lewiecki EM (2011) Combination therapy: the Holy Grail for the treatment of postmenopausal osteoporosis. Curr Med Res Opin 27(7):1493–1497PubMedCrossRef Lewiecki EM (2011) Combination therapy: the Holy Grail for the treatment of postmenopausal osteoporosis. Curr Med Res Opin 27(7):1493–1497PubMedCrossRef
15.
go back to reference Black DJKSLTTJCJ (2005) One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 353:555–565PubMedCrossRef Black DJKSLTTJCJ (2005) One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 353:555–565PubMedCrossRef
16.
go back to reference Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ, PaTH Study Investigators (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349(13):1207–1215PubMedCrossRef Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ, PaTH Study Investigators (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349(13):1207–1215PubMedCrossRef
17.
go back to reference Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S (2011) Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res 26(3):503–511PubMedCrossRef Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S (2011) Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res 26(3):503–511PubMedCrossRef
18.
go back to reference Cosman F, Nieves JW, Zion M, Barbuto N, Lindsay R (2008) Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. Osteoporos Int 19(4):529–535PubMedCrossRef Cosman F, Nieves JW, Zion M, Barbuto N, Lindsay R (2008) Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. Osteoporos Int 19(4):529–535PubMedCrossRef
19.
go back to reference Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F (1997) Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350(9077):550–555PubMedCrossRef Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F (1997) Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350(9077):550–555PubMedCrossRef
20.
go back to reference Shen Y, Gray DL, Martinez DS (2017) Combined pharmacologic therapy in postmenopausal osteoporosis. Endocrinol Metab Clin N Am 46(1):193–206CrossRef Shen Y, Gray DL, Martinez DS (2017) Combined pharmacologic therapy in postmenopausal osteoporosis. Endocrinol Metab Clin N Am 46(1):193–206CrossRef
21.
go back to reference Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R (2001) Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 16(5):925–931PubMedCrossRef Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R (2001) Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 16(5):925–931PubMedCrossRef
22.
go back to reference Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R (2005) Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353(6):566–575PubMedCrossRef Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R (2005) Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353(6):566–575PubMedCrossRef
23.
go back to reference Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV, Krege JH (2009) Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab 94:3772–3780PubMedCrossRef Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV, Krege JH (2009) Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab 94:3772–3780PubMedCrossRef
24.
go back to reference Fogelman I, Fordham JN, Fraser WD, Spector TD, Christiansen C, Morris SA, Fox J (2008) Parathyroid hormone(1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy. Calcif Tissue Int 83(2):85–92PubMedCrossRef Fogelman I, Fordham JN, Fraser WD, Spector TD, Christiansen C, Morris SA, Fox J (2008) Parathyroid hormone(1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy. Calcif Tissue Int 83(2):85–92PubMedCrossRef
25.
go back to reference Idolazzi L, Rossini M, Viapiana O, Braga V, Fassio A, Benini C, Kunnathully V, Adami S, Gatti D (2016) Teriparatide and denosumab combination therapy and skeletal metabolism. Osteoporos Int 27:3301–3307PubMedCrossRef Idolazzi L, Rossini M, Viapiana O, Braga V, Fassio A, Benini C, Kunnathully V, Adami S, Gatti D (2016) Teriparatide and denosumab combination therapy and skeletal metabolism. Osteoporos Int 27:3301–3307PubMedCrossRef
26.
go back to reference Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD (1998) Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102:1627–1633PubMedPubMedCentralCrossRef Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD (1998) Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102:1627–1633PubMedPubMedCentralCrossRef
27.
go back to reference Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie SAM, Zhu Y, Foley K, Lee H, Neer RM (2014) Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab 99:1694–1700PubMedPubMedCentralCrossRef Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie SAM, Zhu Y, Foley K, Lee H, Neer RM (2014) Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab 99:1694–1700PubMedPubMedCentralCrossRef
28.
go back to reference Muschitz C, Kocijan R, Fahrleitner-Pammer A, Lung S, Resch H (2013) Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density. J Bone Miner Res 28:196–205PubMedCrossRef Muschitz C, Kocijan R, Fahrleitner-Pammer A, Lung S, Resch H (2013) Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density. J Bone Miner Res 28:196–205PubMedCrossRef
29.
go back to reference Walker MD, Cusano NE, Sliney J, Romano M, Zhang C, McMahon DJ et al (2013) Combination therapy with risedronate and teriparatide in male osteoporosis. Endocrine 44(1):237–246PubMedCrossRef Walker MD, Cusano NE, Sliney J, Romano M, Zhang C, McMahon DJ et al (2013) Combination therapy with risedronate and teriparatide in male osteoporosis. Endocrine 44(1):237–246PubMedCrossRef
30.
go back to reference Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH (2005) Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 20(11):1905–1911PubMedCrossRef Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH (2005) Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 20(11):1905–1911PubMedCrossRef
31.
go back to reference Ste-Marie LG, Schwartz SL, Hossain A, Desaiah D, Gaich GA (2006) Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy. J Bone Miner Res 21(2):283–291PubMedCrossRef Ste-Marie LG, Schwartz SL, Hossain A, Desaiah D, Gaich GA (2006) Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy. J Bone Miner Res 21(2):283–291PubMedCrossRef
32.
go back to reference Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349(13):1216–1226PubMedCrossRef Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349(13):1216–1226PubMedCrossRef
33.
go back to reference Finkelstein JS, Wyland JJ, Lee H, Neer RM (2010) Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 95(4):1838–1845PubMedPubMedCentralCrossRef Finkelstein JS, Wyland JJ, Lee H, Neer RM (2010) Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 95(4):1838–1845PubMedPubMedCentralCrossRef
34.
go back to reference Reeve J, Mitchell A, Tellez M, Hulme P, Green JR, Wardley-Smith B, Mitchell R (2001) Treatment with parathyroid peptides and estrogen replacement for severe postmenopausal vertebral osteoporosis: prediction of long-term responses in spine and femur. J Bone Miner Metab 19(2):102–114PubMedCrossRef Reeve J, Mitchell A, Tellez M, Hulme P, Green JR, Wardley-Smith B, Mitchell R (2001) Treatment with parathyroid peptides and estrogen replacement for severe postmenopausal vertebral osteoporosis: prediction of long-term responses in spine and femur. J Bone Miner Metab 19(2):102–114PubMedCrossRef
35.
36.
go back to reference Bilezikian JP, Rubin MR (2006) Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis. Curr Osteoporos Rep. 4(1):5–13PubMedCrossRef Bilezikian JP, Rubin MR (2006) Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis. Curr Osteoporos Rep. 4(1):5–13PubMedCrossRef
37.
go back to reference Binkley N, Krueger D (2005) Combination therapy for osteoporosis: considerations and controversy. Curr Osteoporos Rep 3(4):150–154PubMedCrossRef Binkley N, Krueger D (2005) Combination therapy for osteoporosis: considerations and controversy. Curr Osteoporos Rep 3(4):150–154PubMedCrossRef
38.
go back to reference Doggrell SA (2004) Does the combination of alendronate and parathyroid hormone give a greater benefit than either agent alone in osteoporosis. Expert Opin Pharmacother 5(4):955–958PubMedCrossRef Doggrell SA (2004) Does the combination of alendronate and parathyroid hormone give a greater benefit than either agent alone in osteoporosis. Expert Opin Pharmacother 5(4):955–958PubMedCrossRef
39.
go back to reference Garcés C, García LE (2006) Combination of anabolic and antiresorptive agents for the treatment of osteoporosis. Maturitas 54(1):47–54PubMedCrossRef Garcés C, García LE (2006) Combination of anabolic and antiresorptive agents for the treatment of osteoporosis. Maturitas 54(1):47–54PubMedCrossRef
40.
go back to reference Lecart MP, Bruyere O, Reginster JY (2004) Combination/sequential therapy in osteoporosis. Curr Osteoporos Rep. 2(4):123–130PubMedCrossRef Lecart MP, Bruyere O, Reginster JY (2004) Combination/sequential therapy in osteoporosis. Curr Osteoporos Rep. 2(4):123–130PubMedCrossRef
41.
go back to reference Nakamura Y, Suzuki T, Kamimura M, Ikegami S, Murakami K, Uchiyama S, Taguchi A, Kato H (2017) Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women. Bone Res 5:16055PubMedPubMedCentralCrossRef Nakamura Y, Suzuki T, Kamimura M, Ikegami S, Murakami K, Uchiyama S, Taguchi A, Kato H (2017) Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women. Bone Res 5:16055PubMedPubMedCentralCrossRef
43.
go back to reference Higgins Jpt GS. Cochrane handbook for systematic reviews of interventions version 5.1.0. 2011. Wiley-Blackwell. 102–8 Higgins Jpt GS. Cochrane handbook for systematic reviews of interventions version 5.1.0. 2011. Wiley-Blackwell. 102–8
44.
go back to reference Akl EA, Sun X, Busse JW, Johnston BC, Briel M, Mulla S, You JJ, Bassler D, Lamontagne F, Vera C, Alshurafa M, Katsios CM, Heels-Ansdell D, Zhou Q, Mills E, Guyatt GH (2012) Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid. J Clin Epidemiol 65(3):262–267PubMedCrossRef Akl EA, Sun X, Busse JW, Johnston BC, Briel M, Mulla S, You JJ, Bassler D, Lamontagne F, Vera C, Alshurafa M, Katsios CM, Heels-Ansdell D, Zhou Q, Mills E, Guyatt GH (2012) Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid. J Clin Epidemiol 65(3):262–267PubMedCrossRef
45.
go back to reference Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD et al (2011) The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928PubMedPubMedCentralCrossRef Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD et al (2011) The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928PubMedPubMedCentralCrossRef
46.
49.
go back to reference Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56(2):455–463PubMedCrossRef Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56(2):455–463PubMedCrossRef
50.
go back to reference Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S et al (2004) Grading quality of evidence and strength of recommendations. BMJ 328(7454):1490CrossRefPubMed Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S et al (2004) Grading quality of evidence and strength of recommendations. BMJ 328(7454):1490CrossRefPubMed
51.
go back to reference Finkelstein JS, Klibanski A, Arnold AL, Toth TL, Hornstein MD, Neer RM (1998) Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial. JAMA 280(12):1067–1073PubMedCrossRef Finkelstein JS, Klibanski A, Arnold AL, Toth TL, Hornstein MD, Neer RM (1998) Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial. JAMA 280(12):1067–1073PubMedCrossRef
52.
go back to reference Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MD, Schiff I, Neer RM (1994) Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 331(24):1618–1623PubMedCrossRef Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MD, Schiff I, Neer RM (1994) Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 331(24):1618–1623PubMedCrossRef
53.
go back to reference Wermers RA, Recknor CP, Cosman F, Xie L, Glass EV, Krege JH (2008) Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate. Osteoporos Int 19(7):1055–1065PubMedCrossRef Wermers RA, Recknor CP, Cosman F, Xie L, Glass EV, Krege JH (2008) Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate. Osteoporos Int 19(7):1055–1065PubMedCrossRef
54.
go back to reference Schafer AL, Sellmeyer DE, Palermo L, Hietpas J, Eastell R, Shoback DM, Black DM (2012) Six months of parathyroid hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial. J Clin Endocrinol Metab 97(10):3522–3529PubMedPubMedCentralCrossRef Schafer AL, Sellmeyer DE, Palermo L, Hietpas J, Eastell R, Shoback DM, Black DM (2012) Six months of parathyroid hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial. J Clin Endocrinol Metab 97(10):3522–3529PubMedPubMedCentralCrossRef
55.
go back to reference Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, Audran M, Barker C, Anastasilakis AD, Fraser WD, Nickelsen T, EUROFORS Investigators (2008) Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 23(10):1591–1600PubMedCrossRef Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, Audran M, Barker C, Anastasilakis AD, Fraser WD, Nickelsen T, EUROFORS Investigators (2008) Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 23(10):1591–1600PubMedCrossRef
56.
go back to reference Compston J (2012) The use of combination therapy in the treatment of postmenopausal osteoporosis. Endocrine 41(1):11–18PubMedCrossRef Compston J (2012) The use of combination therapy in the treatment of postmenopausal osteoporosis. Endocrine 41(1):11–18PubMedCrossRef
57.
go back to reference Cosman F (2014a) Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches. Curr Osteoporos Rep 12:385–395PubMedCrossRef Cosman F (2014a) Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches. Curr Osteoporos Rep 12:385–395PubMedCrossRef
59.
go back to reference Palacios S, Mejía A (2015) Antiresorptives and anabolic therapy in sequence or combination for postmenopausal osteoporosis. Climacteric 18(4):453–455PubMedCrossRef Palacios S, Mejía A (2015) Antiresorptives and anabolic therapy in sequence or combination for postmenopausal osteoporosis. Climacteric 18(4):453–455PubMedCrossRef
60.
go back to reference Lewiecki EM, Cummings SR, Cosman F (2013) Treat-to-target for osteoporosis: is now the time. J Clin Endocrinol Metab 98:946–953PubMedCrossRef Lewiecki EM, Cummings SR, Cosman F (2013) Treat-to-target for osteoporosis: is now the time. J Clin Endocrinol Metab 98:946–953PubMedCrossRef
61.
go back to reference Cummings SR, Cosman F, Eastell R, Reid IR, Mehta M, Lewiecki EM (2013) Goal-directed treatment of osteoporosis. J Bone Miner Res 28:433–438PubMedCrossRef Cummings SR, Cosman F, Eastell R, Reid IR, Mehta M, Lewiecki EM (2013) Goal-directed treatment of osteoporosis. J Bone Miner Res 28:433–438PubMedCrossRef
62.
go back to reference Michael LE (2017) Osteoporosis: treat-to-target. Curr Osteoporos Rep 15:103–109CrossRef Michael LE (2017) Osteoporosis: treat-to-target. Curr Osteoporos Rep 15:103–109CrossRef
63.
go back to reference Murad MH, Drake MT, Mullan RJ, Mauck KF, Stuart LM, Lane MA, Abu ENO, Erwin PJ, Hazem A, Puhan MA, Li T, Montori VM (2012) Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 97:1871–1880PubMedCrossRef Murad MH, Drake MT, Mullan RJ, Mauck KF, Stuart LM, Lane MA, Abu ENO, Erwin PJ, Hazem A, Puhan MA, Li T, Montori VM (2012) Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 97:1871–1880PubMedCrossRef
64.
go back to reference Cummings SR, Cosman F, Lewiecki EM, Schousboe JT, Bauer DC, Black DM, Brown TD, Cheung AM, Cody K, Cooper C, Diez-Perez A, Eastell R, Hadji P, Hosoi T, De Beur SJ, Kagan R, Kiel DP, Reid IR, Solomon DH, Randall S (2017) Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF working group on goal-directed treatment for osteoporosis. J Bone Miner Res 32:3–10PubMedCrossRef Cummings SR, Cosman F, Lewiecki EM, Schousboe JT, Bauer DC, Black DM, Brown TD, Cheung AM, Cody K, Cooper C, Diez-Perez A, Eastell R, Hadji P, Hosoi T, De Beur SJ, Kagan R, Kiel DP, Reid IR, Solomon DH, Randall S (2017) Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF working group on goal-directed treatment for osteoporosis. J Bone Miner Res 32:3–10PubMedCrossRef
65.
go back to reference Ettinger B, San MJ, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19(5):745–751PubMedCrossRef Ettinger B, San MJ, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19(5):745–751PubMedCrossRef
66.
go back to reference Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SAM (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386:1147–1155PubMedPubMedCentralCrossRef Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SAM (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386:1147–1155PubMedPubMedCentralCrossRef
67.
go back to reference Boonen S, Ferrari S, Miller PD, Eriksen EF, Sambrook PN, Compston J, Reid IR, Vanderschueren D, Cosman F (2012) Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk—a perspective. J Bone Miner Res 27:963–974PubMedCrossRef Boonen S, Ferrari S, Miller PD, Eriksen EF, Sambrook PN, Compston J, Reid IR, Vanderschueren D, Cosman F (2012) Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk—a perspective. J Bone Miner Res 27:963–974PubMedCrossRef
Metadata
Title
Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis: a systematic review and meta-analysis of randomized controlled trials
Authors
S. Lou
H. Lv
P. Yin
Z. Li
P. Tang
Y. Wang
Publication date
01-01-2019
Publisher
Springer London
Published in
Osteoporosis International / Issue 1/2019
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-018-4790-4

Other articles of this Issue 1/2019

Osteoporosis International 1/2019 Go to the issue